The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it.
A follow-up question about semaglutide solutions that I did not know to ask the first time.
The earlier thread answered what I asked. What I should have asked is below, and I think it is the one that matters.
Gallbladder events appear in the labelling for this class and are more common with larger, faster weight reduction. The mechanism is not specific to the drug — rapid weight loss by any route carries the same association.
Post #7 is right about the mechanism and I think understates the practical bit.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
The reasoning is more useful than the number, which is why I have shown it.
Coming back to post #14, because the follow-up matters more than the original answer.
Semaglutide solutions is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Coming back to post #36, because the follow-up matters more than the original answer.
On the "does it stop working" question: tolerance in the pharmacological sense is not what the withdrawal trials show. What they show is that the effect persists while treatment continues and reverses when it stops, which is a different finding with different implications.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
The arithmetic in post #67 is right; the assumption feeding it is the part to check.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
On post #76 — agreed on the reasoning, with one qualification.
The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.
A modest claim, modestly supported.
Read the full topic (80 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I would like to know what…
|
+23 | 27 | 9.9k | 1mo |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
|
2 | 63k | 5mo | |
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because…
|
2 | 14k | 2mo | |
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
2 | 49k | 2y | |
|
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully
Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
|
+1 | 5 | 11k | 20mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Cagrilintide alone:…
|
+27 | 31 | 1.2k | 22h |
|
Food effects on oral incretin absorption: what is documented
On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Food effects on oral incretin, from the point of view of someone who has read…
|
2 | 4.4k | 12mo | |
|
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Posting a small dataset on reverse causation. It is mine, it is uncontrolled, and…
|
+10 | 14 | 11k | 7mo |
|
[2026 update] Correlation in a self-tracked dataset: what it can support
Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. Posting a small dataset on Correlation. It is mine, it is…
|
2 | 31k | 6h | |
|
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Posting a small dataset on SURMOUNT-4 and…
|
+58 | 64 | 17k | 13mo |